Comparative assessment of Safety and Efficacy of Vortioxetine with Escitalopram in patients with MDD: a randomized, comparative, parallel group, open-label study - MDD= Major Depressive Disorder

Dr Anshul Upadhyay0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with primary diagnosed depression with MADRS (Montgomeryâ??Ã?sberg Depression Rating Scale) score >22 and no other concurrent psychiatric disorders at baseline.
•2.Patients of 18 â?? 60 years of age
•3.Subjects of either gender
•4.Subjects willing to give written informed consent.

•1.Patients with history of substance abuse.
•2.Patients with two failed previous antidepressant treatments (of at least 6 weeks in duration)
•3.Patient with any other long-term treatment like anti-hypertensive, anti-diabetic,
•anti-tubercular
•4.Patients with neurological disorders (dementia, stroke, seizures), obesity with
•functional impairment, serious or not stabilized organic disorder (neoplastic,
•cardiovascular, pulmonary, uncontrolled diabetes).
•5.Patients who pose a significant risk of suicide, had a score of 5 on item 10
•(suicidal thoughts) of the MADRS or had made a suicide attempt in the previous 6 months.
•6.Patients who have received electroconvulsive therapy in the preceding 6 months.
•7.Patients who have MADRS (Montgomeryâ??Ã?sberg Depression Rating Scale) score <22 at baseline

发起方

Dr Anshul Upadhyay